| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
OncoCyte Corporation (NASDAQ: OCX)
OCX Technical Analysis
3
| As on 17th Jun 2025 OCX STOCK Price closed @ 3.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.95 & Buy for SHORT-TERM with Stoploss of 3.05 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OCXSTOCK Price
| Open | 2.77 | Change | Price | % |
| High | 3.21 | 1 Day | 0.47 | 17.22 |
| Low | 2.71 | 1 Week | 0.23 | 7.74 |
| Close | 3.20 | 1 Month | 0.28 | 9.59 |
| Volume | 100514 | 1 Year | 0.35 | 12.28 |
| 52 Week High 4.17 | 52 Week Low 1.96 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 0.00% |
| NVDA | 143.85 | -1.12% |
| GNLN | 0.01 | 0.00% |
| PCSA | 0.32 | 33.33% |
| INTC | 21.08 | -1.91% |
| LMDX | 0.02 | 0.00% |
| LCID | 2.19 | -1.35% |
| NCNA | 0.10 | -16.67% |
| TSLA | 322.16 | 0.03% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OCX Daily Charts |
OCX Intraday Charts |
Whats New @ Bazaartrend |
OCX Free Analysis |
|
|
OCX Important Levels Intraday
| RESISTANCE | 4.16 |
| RESISTANCE | 3.85 |
| RESISTANCE | 3.66 |
| RESISTANCE | 3.47 |
| SUPPORT | 2.93 |
| SUPPORT | 2.74 |
| SUPPORT | 2.55 |
| SUPPORT | 2.24 |
OCX Forecast June 2025
| 4th UP Forecast | 4.49 |
| 3rd UP Forecast | 4.08 |
| 2nd UP Forecast | 3.82 |
| 1st UP Forecast | 3.57 |
| 1st DOWN Forecast | 2.83 |
| 2nd DOWN Forecast | 2.58 |
| 3rd DOWN Forecast | 2.32 |
| 4th DOWN Forecast | 1.91 |
OCX Weekly Forecast
| 4th UP Forecast | 6.09 |
| 3rd UP Forecast | 5.16 |
| 2nd UP Forecast | 4.59 |
| 1st UP Forecast | 4.02 |
| 1st DOWN Forecast | 2.38 |
| 2nd DOWN Forecast | 1.81 |
| 3rd DOWN Forecast | 1.24 |
| 4th DOWN Forecast | 0.31 |
OCX Forecast2025
| 4th UP Forecast | 8.65 |
| 3rd UP Forecast | 6.9 |
| 2nd UP Forecast | 5.82 |
| 1st UP Forecast | 4.74 |
| 1st DOWN Forecast | 1.66 |
| 2nd DOWN Forecast | 0.58 |
| 3rd DOWN Forecast | -0.5 |
| 4th DOWN Forecast | -2.25 |
OncoCyte Corporation ( NASDAQ USA Symbol : OCX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OCX Business Profile
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California. Address: 15 Cushing, Irvine, CA, United States, 92618
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service